Nico Chen, an analyst from DBS, maintained the Buy rating on Siemens Healthineers AG (SEMHF – Research Report). The associated price target was raised to €59.00.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Nico Chen has given his Buy rating due to a combination of factors including Siemens Healthineers AG’s strong revenue growth and innovative advancements. The company reported a 6.8% year-over-year increase in revenue for the second quarter of fiscal year 2025, surpassing its full-year guidance. The imaging segment, in particular, showed impressive growth, driven by high demand and operational efficiency.
Siemens Healthineers is leading the market with its innovative photon counting CT technology, which has received FDA approval and offers significant advantages over conventional CT systems. This technology enhances image quality and reduces radiation dose, positioning Siemens as a first-mover in this space. Despite potential challenges from geopolitical uncertainties and tariff impacts, the company’s robust performance and technological leadership support the Buy rating, with a target price set at EUR59.0.